It is, therefore, intriguing to speculate that induction of autophagy/lysosomal activity in combination with PPARα agonist therapy could yield better results in patients with NAFLD/NASH. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.